RBM39 methylation by PRMT6 increases RBM39 stability by inhibiting its ubiquitination. by Tongjia Zhang (16496661)

Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

“…Lower income levels are associated with decreased survival, potentially due to delays in diagnosis or treatment and a higher probability of advanced staging at diagnosis, These inequities persist even among relatively advantaged populations, such as formal employee who are assumed to have fewer barriers to accessing healthcare services compared to informal workers.…”

LLL12B, APTO-253, and VK-1727 inhibit cell growth and induce apoptosis in LCL. by Huanzhou Xu (8129922)

Table 1_Plant-based diets and total and cause-specific mortality: a meta-analysis of prospective studies.docx by Qiwang Mo (9091292)

“…Participants in the highest quintile of both the PDI and hPDI had a significantly decreased risk of all-cause mortality (pooled HR_PDI = 0.85; 95% CI: 0.80–0.90; pooled HR_hPDI = 0.86; 95% CI: 0.81–0.92) compared to participants in the lowest quintile. …”

Image 2_Plant-based diets and total and cause-specific mortality: a meta-analysis of prospective studies.tif by Qiwang Mo (9091292)

“…Participants in the highest quintile of both the PDI and hPDI had a significantly decreased risk of all-cause mortality (pooled HR_PDI = 0.85; 95% CI: 0.80–0.90; pooled HR_hPDI = 0.86; 95% CI: 0.81–0.92) compared to participants in the lowest quintile. …”

Image 1_Plant-based diets and total and cause-specific mortality: a meta-analysis of prospective studies.tif by Qiwang Mo (9091292)

“…Participants in the highest quintile of both the PDI and hPDI had a significantly decreased risk of all-cause mortality (pooled HR_PDI = 0.85; 95% CI: 0.80–0.90; pooled HR_hPDI = 0.86; 95% CI: 0.81–0.92) compared to participants in the lowest quintile. …”

Table 1_Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis.docx by Dongsheng Wu (2469307)

“…</p>Results<p>The randomized controlled trials (RCTs) included in this review examined dietary supplementation with eight polyphenols—curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive oral AKL1 treatment—across a total of 894 participants. This systematic review and meta-analysis revealed that, compared to a placebo; ① Curcumin significantly reduced systolic blood pressure (SBP) and improved FEV1(SMD=-0.82, 95%CI -1.53 to -0.11); ② Salidroside was effective in reducing thrombotic markers (TT, D-D), inflammatory factors (TNF-α) and symptom scores (CAT) (p<0.01); ③ Resveratrol significantly downregulates serum TNF-α and IL-8 levels (p=0.003); ④ Anthocyanins may accelerate lung function decline (decreased FEV1/FVC, which needs to be interpreted with caution); ⑤ Other polyphenols (quercetin, pomegranate juice, AKL1, etc.) did not show significant efficacy or insufficient evidence. …”

Table 1_The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease: a cohort study.docx by Chen Huang (202847)

“…</p>Results<p>Among the 176 included patients, 99 (56%) were in the IFX monotherapy group, and 77 (44%) were in the IFX + PEN group. A significantly higher proportion of patients in the IFX + PEN group achieved clinical response (defined as a CDAI decrease ≥70 points) compared to those in the IFX group at 14 weeks (87.01% vs. 74.75%, p = 0.043), as well as a higher proportion achieving endoscopic remission at 54 weeks (84.42% vs. 65.66%, p = 0.005). …”

Primers for qPCR. by Xiaoyi Shi (3825754)

“…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”

S1 Raw data - by Xiaoyi Shi (3825754)

“…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”

The chemical structure of melatonin. by Xiaoyi Shi (3825754)

“…In contrast, melatonin supplementation blocked the PGAM5-mPTP axis and thus decreased cell death, providing a protective advantage to hepatocytes in I/R. …”

Study design and plasma viral load. by Zoey K. Wallis (17725175)

Table 4_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx by Junzhe Chen (5729912)

“…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …”

Supplementary Material for: Seizure Burden Before and After Lidocaine as Add-on Therapy in (a)EEG-Confirmed Neonatal Seizures by figshare admin karger (2628495)

“…After LDC administration, median TSB decreased significantly from 31 (interquartile range, IQR 16–68) to 0 minutes (IQR 0–0, p<0.01), and MSB from 10 (IQR 6–41) to 0 min/hour (IQR 0–0, p<0.01). …”

Table 3_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx by Junzhe Chen (5729912)

“…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …”

Table 1_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.pdf by Junzhe Chen (5729912)

“…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …”

Table 2_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx by Junzhe Chen (5729912)

“…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …”

DEGs and enrichment analysis in HepG2 cells expressing HBx. by Jianhua Zhong (11351726)

Elevated IL-6 response to PAMP stimulated whole blood of calves diagnosed with BRD by TUS. by Cian Reid (17274007)

STAT3 and MYC enrich at <i>STAT3</i> and <i>ZC3H18</i> promoters while EBNA1 predominantly enriches at the <i>BKRF1</i> (EBNA1) promoter. by Huanzhou Xu (8129922)